Marinus Pharma Slides After IV Ganaxolone Trial Misses Endpoint

Dow Jones06-17

By Dean Seal

Shares of Marinus Pharmaceuticals slid after the company said a trial of its intravenous ganaxolone for the treatment of refractory status epilepticus failed to meet a co-primary endpoint.

The stock was down 5.1% at $1.39 in premarket trading. Shares had fallen 87% year-to-date when the market closed last week.

The commercial-stage pharmaceutical company said on Monday morning that the Phase 3 trial of IV ganaxolone met a co-primary endpoint of demonstrating rapid cessation of status epilepticus, a type of seizure.

However, the trial failed to achieve statistical significance on a second co-primary endpoint of the proportion of patients not progressing to IV anesthesia.

Marinus said it would continue to analyze the trial data and engage with regulators on a potential path forward for IX ganaxolone in refractory status epilepticus.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

June 17, 2024 07:40 ET (11:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444216552?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-17 19:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444216552","market":"fut","top_or_hot":-1,"title":"Marinus Pharma Slides After IV Ganaxolone Trial Misses Endpoint","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/MRNS\">Marinus Pharmaceuticals</a> slid after the company said a trial of its intravenous ganaxolone for the treatment of refractory status epilepticus failed to meet a co-primary endpoint. \n</p>\n<p>\n  The stock was down 5.1% at $1.39 in premarket trading. Shares had fallen 87% year-to-date when the market closed last week. \n</p>\n<p>\n  The commercial-stage pharmaceutical company said on Monday morning that the Phase 3 trial of IV ganaxolone met a co-primary endpoint of demonstrating rapid cessation of status epilepticus, a type of seizure. \n</p>\n<p>\n  However, the trial failed to achieve statistical significance on a second co-primary endpoint of the proportion of patients not progressing to IV anesthesia. \n</p>\n<p>\n  Marinus said it would continue to analyze the trial data and engage with regulators on a potential path forward for IX ganaxolone in refractory status epilepticus. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 17, 2024 07:40 ET (11:40 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Marinus Pharma Slides After IV Ganaxolone Trial Misses Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarinus Pharma Slides After IV Ganaxolone Trial Misses Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-17 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Dean Seal \n\n\n \n\n\n  Shares of Marinus Pharmaceuticals slid after the company said a trial of its intravenous ganaxolone for the treatment of refractory status epilepticus failed to meet a co-primary...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNS","symbol_name":"Marinus Pharmaceuticals","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2444216552","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444216552","pubTimestamp":1718624400,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Marinus Pharmaceuticals slid after the company said a trial of its intravenous ganaxolone for the treatment of refractory status epilepticus failed to meet a co-primary endpoint.The stock was down 5.1% at $1.39 in premarket trading. Shares had fallen 87% year-to-date when the market closed last week.The commercial-stage pharmaceutical company said on Monday morning that the Phase 3 trial of IV ganaxolone met a co-primary endpoint of demonstrating rapid cessation of status epilepticus, a type of seizure.However, the trial failed to achieve statistical significance on a second co-primary endpoint of the proportion of patients not progressing to IV anesthesia.Marinus said it would continue to analyze the trial data and engage with regulators on a potential path forward for IX ganaxolone in refractory status epilepticus.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNS":"Marinus Pharmaceuticals","BK4007":"制药"},"translate_title":"Marinus Pharma在静脉注射加奈索酮试验未达到终点后股价下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNS":0.9},"content_text":"By Dean Seal \n\n\n \n\n\n  Shares of Marinus Pharmaceuticals slid after the company said a trial of its intravenous ganaxolone for the treatment of refractory status epilepticus failed to meet a co-primary endpoint. \n\n\n  The stock was down 5.1% at $1.39 in premarket trading. Shares had fallen 87% year-to-date when the market closed last week. \n\n\n  The commercial-stage pharmaceutical company said on Monday morning that the Phase 3 trial of IV ganaxolone met a co-primary endpoint of demonstrating rapid cessation of status epilepticus, a type of seizure. \n\n\n  However, the trial failed to achieve statistical significance on a second co-primary endpoint of the proportion of patients not progressing to IV anesthesia. \n\n\n  Marinus said it would continue to analyze the trial data and engage with regulators on a potential path forward for IX ganaxolone in refractory status epilepticus. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2024 07:40 ET (11:40 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444216552"}